Larson Financial Group’s Sonnet BioTherapeutics SONN Stock Holding History

Larson Financial Group’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,303	Closed	-$19.7K	–	3643
2025 Q3	$19.7K	Buy	+4,303	New	+$19.1K	﹤0.01%	1653

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Larson Financial Group's SONN Position: Q4 2025 in Review

Larson Financial Group sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 4,303 shares — an estimated $19.7K sold.

Larson Financial Group first reported a position in SONN in Q3 2025 and held it in 1 quarter. The position peaked at $19.7K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

Larson Financial Group reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Larson Financial Group sold 4,303 Sonnet BioTherapeutics shares in Q4 2025, an estimated $19.7K.
Larson Financial Group first reported a position in Sonnet BioTherapeutics in Q3 2025 and held it in 1 quarter.
Larson Financial Group's Sonnet BioTherapeutics position peaked at $19.7K in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Larson Financial Group's 13F filing for Q4 2025, filed 6 Feb 2026.